Skip to main content

Drug Interactions between deferoxamine and Mega-C-Acid Plus

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

ascorbic acid deferoxamine

Applies to: Mega-C-Acid Plus (ascorbic acid) and deferoxamine

ADJUST DOSE: Although ascorbic acid is commonly given during deferoxamine treatment, cardiac disorders (left ventricular dysfunction) and cataracts have been reported with high doses (more than 200 mg/day) or long-term use. Higher doses of vitamin C do not provide any additional benefit. The mechanism is unknown.

MANAGEMENT: Ascorbic acid should not be initiated until after the first month of treatment with deferoxamine. Doses should be given on the same days that deferoxamine is administered. Doses should not exceed 200 mg per day (in divided doses) for adults, 50 mg per day for children younger than 10 years, and 100 mg per day for children over 10 years. Cardiac function should be monitored during concomitant use.

References

  1. "Multum Information Services, Inc. Expert Review Panel"
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer